Suppr超能文献

非小细胞肺癌中可切除N2期的识别:单中心经验及美国监测、流行病学和最终结果(SEER)数据库综述

Identification of Resectable N2 in NSCLC: A Single Center Experience and Review of the SEER Database.

作者信息

Wang Yan-Qing, Liu Xu-Dong, Bai Wen-Liang, Li Shan-Qing

机构信息

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Medical Science Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

出版信息

Front Oncol. 2021 Apr 26;11:647546. doi: 10.3389/fonc.2021.647546. eCollection 2021.

Abstract

BACKGROUND

Non-small cell lung carcinoma (NSCLC) with ipsilateral and/or subcarinal mediastinal lymphatic spread (N2) is a heterogeneous disease. The role of surgical resection in patients with N2 NSCLC remains controversial and no survival-based definition of "resectable N2" exists. The purpose of this study is to evaluate the factors that potentially affect the survival of N2 NSCLC patients who receive surgical resection and to define "resectable N2" based on the survival benefits.

METHODS

Data from the open Surveillance, Epidemiology, and End Results (SEER) database from the National Cancer Institute in the United States were used to construct a nomogram. Patients who received surgery between 2010 and 2015 for N2 NSCLC were included. Independent prognostic factors for survival identified through Cox regression analysis were used to create the nomogram. The C-index, receiver operating characteristics (ROC) analyses, calibration curves, and risk stratification were used to evaluate the nomogram. The nomogram was also validated using data from 222 patients from Peking Union Medical College Hospital (PUMCH). Furthermore, lung cancer-related deaths were compared using competitive risk analysis.

RESULTS

In total, 4267 patients were included in the SEER cohort. Male gender, old age, high T stage and grade, adenosquamous and squamous cell carcinoma, lower lobe and overlapping lesions, extended lobe or bilobectomy and pneumonectomy, no chemotherapy, radiation before and after surgery, positive number of lymph nodes, and lymph node ratio (LNR) were identified as independent risk factors for higher mortality. The nomogram was created using these parameters. The C-index was 0.665 (95% confidence interval (CI), 0.651-0.679) and 0.722 (95% CI, 0.620-0.824) in the SEER and PUMCH cohorts, respectively. The calibration curves showed satisfactory consistency between the predicted and actual survival status in both the SEER and PUMCH cohorts. Competitive risk analysis confirmed that the variables in the nomogram, except radiation, are risk factors for prognosis.

CONCLUSIONS

"Resectable N2" should be assessed by a multidisciplinary team. The novel nomogram developed in this study may help with clinical decision-making for this patient population.

摘要

背景

伴有同侧和/或隆突下纵隔淋巴结转移(N2)的非小细胞肺癌(NSCLC)是一种异质性疾病。手术切除在N2期NSCLC患者中的作用仍存在争议,且不存在基于生存情况的“可切除N2”定义。本研究的目的是评估可能影响接受手术切除的N2期NSCLC患者生存的因素,并基于生存获益来定义“可切除N2”。

方法

使用来自美国国立癌症研究所开放的监测、流行病学和最终结果(SEER)数据库的数据构建列线图。纳入2010年至2015年间因N2期NSCLC接受手术的患者。通过Cox回归分析确定的生存独立预后因素用于创建列线图。使用C指数、受试者工作特征(ROC)分析、校准曲线和风险分层来评估列线图。还使用北京协和医院(PUMCH)222例患者的数据对列线图进行验证。此外,使用竞争风险分析比较肺癌相关死亡情况。

结果

SEER队列共纳入4267例患者。男性、老年、高T分期和分级、腺鳞癌和鳞状细胞癌、下叶和重叠病变、扩大肺叶或双肺叶切除及全肺切除、未化疗、手术前后放疗、淋巴结阳性数和淋巴结比率(LNR)被确定为更高死亡率独立危险因素。使用这些参数创建了列线图。SEER队列和PUMCH队列的C指数分别为0.665(95%置信区间(CI),0.651 - 0.679)和0.722(95%CI,0.620 - 0.824)。校准曲线显示SEER队列和PUMCH队列中预测生存状态与实际生存状态之间具有令人满意的一致性。竞争风险分析证实,列线图中的变量(放疗除外)是预后危险因素。

结论

“可切除N2”应由多学科团队进行评估。本研究开发的新型列线图可能有助于该患者群体的临床决策。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验